ID,Seed,Run time,Rate of gonorrhea cases (average incidence after epidemic warm-up),Time-averaged proportion of cases CIP-S (average incidence after epidemic warm-up),Time-averaged proportion of cases TET-S (average incidence after epidemic warm-up),Time-averaged proportion of cases CRO-S (average incidence after epidemic warm-up),Time-averaged proportion of cases CIP/TET-NS (average incidence after epidemic warm-up),"Time-averaged proportion of cases treated successfully with CIP, TET, or CRO (average incidence after epidemic warm-up)",Time-averaged proportion of cases treated successfully with CIP (average incidence after epidemic warm-up),Time-averaged proportion of cases treated successfully with TET (average incidence after epidemic warm-up),Time-averaged proportion of cases treated successfully with CRO (average incidence after epidemic warm-up),Duration of 1st line therapy with CRO (after epidemic warm-up),Duration of 1st line therapy with Drug M (after epidemic warm-up)
0,825563396,10.06011176109314,0.06329216534031751,0.5950299252067379,0.16125251802312193,0.933119055889986,0.8145510715113667,0.47443059096958207,0.0,0.0,0.47443059096958207,11.0,13.0
1,1765374533,10.056695222854614,0.05880907253335316,0.6259700821541234,0.16668525241162313,0.927725172844863,0.8139253818317974,0.5139199872215444,0.0,0.0,0.5139199872215444,12.0,12.0
2,825253156,10.070061445236206,0.0741244211600303,0.7526139352344832,0.17582552476760183,0.954596155832596,0.8000145217315087,0.5132985617094111,0.0,0.0,0.5132985617094111,12.0,12.0
3,1344319995,9.883275985717773,0.058440777417406026,0.7818829397428783,0.19620423593194636,0.9519463798234677,0.7765140566659625,0.5958496308050013,0.0,0.0,0.5958496308050013,14.0,10.0
